...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Annual Financial Reporting

Fuzzy, relying on Zenith to save the day seems a long way off seeing that all the Clinical Trials are not into Phase 3. Phase 3 Trials can run for a few years. We need something more immediate.

We will never know why Shawn Lu resigned.

HL converting debentures to common shares may not be all that bad and dethroning DM in the process.  Beats HL taking possession of the IPs. But even that may not be that easy for HL to do when there is the Ori Group and Eastern to run interference. 

 

Koo

Share
New Message
Please login to post a reply